PROMISE Registry on Standardized Evaluation of PSMA-PET and Outcome in Prostate Cancer

Background:

PROMISE criteria have been defined for standardized reporting of Prostate-Specific Membrane Antigen (PSMA) PET whole-body stage of prostate cancer. PSMA PET disease extent by PROMISE has been associated with oncologic outcome.

Need:

Improved prognostication across various stages of prostate cancer is needed for management guidance and study design.

Aim:

1. To assess the prognostic value of PSMA PET
2. To compare the prognostic value of PSMA PET with clinical prognostic scores in patients with prostate cancer at various disease stages

Inclusion:

• Adult patients with
• biopsy/histo proven prostate cancer who
• underwent PSMA PET (any type)
• for staging or re-staging at any stage and who
• have at least 3-year overall survival follow-up data available will be included consecutively.

Exclusion:

• Patients with neuroendocrine prostate cancer
• Patients with metastasized or disseminated malignancy other than prostate cancer